Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-a
Research output: Contribution to journal › Journal article › Research › peer-review
Heterogeneity in the hepatitis C virus (HCV) protein NS5A influences its sensitivity to interferon-based therapy. Furthermore, NS5A is an important target for development of HCV-specific inhibitors. We aimed to develop recombinant infectious cell culture systems that express NS5A from isolates of the 7 major HCV genotypes, and determining their sensitivity to a specific NS5A inhibitor and to interferon-a.
| Original language | English |
|---|---|
| Journal | Gastroenterology Today |
| Volume | 140 |
| Issue number | 3 |
| Pages (from-to) | 1032-42 |
| Number of pages | 11 |
| ISSN | 0969-0131 |
| DOIs | |
| Publication status | Published - 2011 |
- Antiviral Agents, Cell Line, Tumor, Cell Survival, Dose-Response Relationship, Drug, Enzyme Inhibitors, Genotype, Hepacivirus, High-Throughput Screening Assays, Humans, Imidazoles, Interferon-alpha, Mutation, Phenotype, Recombinant Proteins, Time Factors, Viral Nonstructural Proteins, Virus Replication
Research areas
ID: 40330172